N
NETRIS Pharma
Biotech & Life Sciences · Lyon, France · Founded 2008
NETRIS Pharma developed NP137, a humanized monoclonal antibody targeting NETRIN-1, which inhibits tumor growth and reduces immune checkpoint inhibitor resistance in preclinical models MoreLess
Operator of a biopharmaceutical company intended to drive superior clinical benefits for patients in the treatment of cancer. The company's therapies work by targeting the dependence receptors to effectively restore the dependence receptor apoptosis signaling pathway in the absence of the required stimulus, enabling physicians and doctors to effectively cure cancers. Keywords: Pharmaceuticals and Biotechnology, Cancer Therapy, Cancer Treatment, Epithelial To Mesenchymal, Oncology Cure, Oncology Drug, Resistance To Treatment, Therapeutic Drug, Therapeutic Molecules, Therapy Research.
Talent graph
NETRIS Pharma's talent
Source: Dealroom Talent Intelligence.
Investors
3 investors on NETRIS Pharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where NETRIS Pharma has talent and traffic
team presence
Market sentiment
What the market is saying about NETRIS Pharma
An AI-synthesized read of the highest-engagement posts about NETRIS Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NETRIS Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.